C25 (Rubraca 250 mg)
Generic Name: rucaparib
Pill with imprint C25 is White, Four-sided and has been identified as Rubraca 250 mg. It is supplied by Clovis Oncology, Inc..
Rubraca is used in the treatment of ovarian cancer; prostate cancer and belongs to the drug class PARP inhibitors. Rubraca 250 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for C25
Rubraca
- Generic Name
- rucaparib
- Imprint
- C25
- Strength
- 250 mg
- Color
- White
- Size
- 15.00 mm
- Shape
- Four-sided
- Availability
- Prescription only
- Drug Class
- Parp inhibitors
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Clovis Oncology, Inc.
- Manufacturer
- Clovis Oncology, Inc.
- National Drug Code (NDC)
- 69660-0202
- Inactive Ingredients
-
microcrystalline cellulose,
sodium starch glycolate type A potato,
silicon dioxide,
magnesium stearate,
titanium dioxide,
magnesium silicate
Note: Inactive ingredients may vary.
Related Images for "C25"
More about Rubraca (rucaparib)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Pricing & Coupons
- En Español
- Drug class: PARP inhibitors
- FDA Approval History
Consumer resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.